Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. METHODS: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T-C-A) or camrelizumab and apatinib alone (C-A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety. RESULTS: A total of 252 HCC patients were included (T-C-A group, n = 183; C-A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T-C-A group compared to the C-A group (24.2 months [95% CI: 21.4-33.4] vs. 15.2 months [95% CI: 9.8-21.0]; p < 0.001). The T-C-A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8-12.2], compared to 4.9 months [95% CI: 4.0-12.5] in the C-A group (p < 0.001). Further, the ORR was higher in the T-C-A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T-C-A group and 14.5% in the C-A group. CONCLUSION: The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.(Study series number CHANCE 2311).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma
- Date Crossref
- 31/03/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kunming Medical University Department of Minimally Invasive Intervention pays non établi dans la noticeUniversité ou école supérieure
-
Zhongda Hospital Southeast University Basic Medicine Research and Innovation Center of Ministry of Education pays non établi dans la noticeÉtablissement de santé
-
Central South University pays non établi dans la noticeUniversité ou école supérieure
-
Second Xiangya Hospital of Central South University pays non établi dans la noticeÉtablissement de santé
-
Nanfang Hospital State Key Laboratory of Organ Failure Research pays non établi dans la noticeÉtablissement de santé
-
Sichuan Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Southern Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Soochow University Department of Interventional Radiology pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Soochow University pays non établi dans la noticeÉtablissement de santé
-
Shandong Provincial Hospital pays non établi dans la noticeÉtablissement de santé
-
Shandong First Medical University pays non établi dans la noticeUniversité ou école supérieure
-
National Clinical Research Center for Digestive Diseases pays non établi dans la noticeÉtablissement de santé
Department of Minimally Invasive Intervention — Kunming Medical University, Basic Medicine Research and Innovation Center of Ministry of Education — Zhongda Hospital Southeast University et Central South University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.